Exhibit (a)(1)(E)
U.S. Offer to Purchase For Cash
ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS AND
ALL SHARES REPRESENTED BY OUTSTANDING AMERICAN DEPOSITARY
SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED,
of
ABLYNX NV
at
€45.00 PER SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST
and
€45.00 PER AMERICAN DEPOSITARY SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST
Pursuant to the Offer to Purchase dated April 4, 2018
by
SANOFI
THE U.S. OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON MAY 4, 2018, UNLESS THE U.S. OFFER IS EXTENDED OR EARLIER TERMINATED.
April 4, 2018
To Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees:
We have been engaged by Sanofi, a Frenchsociété anonyme (“Offeror”), to act as information agent (the “Information Agent”) in connection with Offeror’s offer to purchase up to 100% of the issued and outstanding ordinary shares, no nominal value (“Shares”) of Ablynx NV, a Belgiannaamloze vennootschap(the “Company”) from U.S. holders (within the meaning of Rule14d-1(d) under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and up to 100% of the outstanding Shares of the Company represented by American Depositary Shares of the Company (each, an “ADS” and collectively, “ADSs”) issued by JPMorgan Chase Bank, N.A., acting as depositary from all holders (the “Depositary”), pursuant to that certain Deposit Agreement, dated as of September 5, 2014, among the Company, the Depositary and all holders from time to time of American depositary receipts (“ADRs”) issued thereunder (as amended, the “Deposit Agreement”), wherever located, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, the related Share Acceptance Form, the related ADS Letter of Transmittal and the related Share Withdrawal Form, as applicable (which, together with the Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “U.S. Offer”). Please furnish copies of the enclosed materials to those of your clients that are (i) U.S. holders and for whom you hold Shares and/or (ii) holders of ADS and for whom you hold ADSs, in each case, registered in your name or in the name of your nominee.
The conditions to the U.S. Offer are described in Section 15 of the Offer to Purchase.
For your information and for forwarding to your clients for whom you hold ADSs, wherever located, and Shares held by U.S. holders registered in your name or in the name of your nominee, we are enclosing the following documents:
1. The Offer to Purchase;
2. The Share Acceptance Form;
3. The ADS Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on IRS FormW-9) for your use in accepting the U.S. Offer and tendering ADSs and for the information of your clients;